Whoa, $CELG just terminated its anti-CD47 trial in AML/MDS -> $TRIL $FTSV $SURF "Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion" https://cli

13:21 EDT 9 Oct 2018 | Andy Biotech

Whoa, $CELG just terminated its anti-CD47 trial in AML/MDS -> $TRIL $FTSV $SURF "Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion" https://clinicaltrials.gov/ct2/show/NCT02641002 …

More From BioPortfolio on "Whoa, $CELG just terminated its anti-CD47 trial in AML/MDS -> $TRIL $FTSV $SURF "Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion" https://cli"